Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%

Redmile Group added 1,316,390 shares of Scholar Rock Holding Corporation in the fourth quarter; the estimated trade value was $49.37 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $84.58 million, reflecting both new purchases and stock price changes.

The Motley Fool • Feb 22, 2026

Scholar Rock to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference: Schol.

Business Wire • Feb 18, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 114,668 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 64,226 shares of common stock and inducement restricted stock units, covering an aggregate of 50,442 shares of its common stock. The awards are subject to all terms and conditions and other provis.

Business Wire • Feb 13, 2026

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telep.

Business Wire • Feb 10, 2026

Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026

Mo Qatanani sold 14,898 shares directly for a transaction value of approximately $695,938 on Jan. 22, 2026, at a weighted average price of $46.71 per share. The sale represented 14.82% of Qatanani's direct holdings, reducing direct ownership to 85,660 shares, which equates to 0.08% of shares outstanding.

The Motley Fool • Feb 1, 2026

Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026

Scholar Rock Highlights 2026 Strategic Priorities

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today provided a corporate update and highlighted its strategic priorities for 2026. “We believe 2026 will be a transformative year for Sc.

Business Wire • Jan 12, 2026

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PST (.

Business Wire • Jan 5, 2026

Scholar Rock: Apitegromab's Path Forward Remains Intact, Maintaining Buy Rating

I maintain a buy rating on Scholar Rock, raising my target price to $97, reflecting increased confidence in apitegromab's approval and commercial prospects. FDA setbacks are manufacturing-related, not clinical, with no new efficacy or safety concerns; remediation and a second CDMO are underway. Topline phase 3 data support apitegromab's novel mechanism and broad label potential, materially expanding SRRK's addressable market and pricing power.

Seeking Alpha • Jan 6, 2026

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away

New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP's 13F reportable assets under management.

The Motley Fool • Dec 3, 2025